Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Co-expression of recombinant immune checkpoint receptor and immune checkpoint inhibiting molecules and application

A technology of checkpoints and receptors, applied in the field of co-expression and application of recombinant immune checkpoint receptors and immune checkpoint inhibitory molecules, to achieve the effect of improving targeted killing effect

Inactive Publication Date: 2018-01-16
LIFESEQ LTDRP
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, tumor immunotherapy still needs further in-depth research and development to enhance clinical efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Co-expression of recombinant immune checkpoint receptor and immune checkpoint inhibiting molecules and application
  • Co-expression of recombinant immune checkpoint receptor and immune checkpoint inhibiting molecules and application
  • Co-expression of recombinant immune checkpoint receptor and immune checkpoint inhibiting molecules and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0277] Example 1 Construction of vectors for co-expression of non-functional EGFR receptors, PD1-silencing shRNA (shPD1, iPD1) and PD1-CD28-CD3zeta recombinant receptors

[0278] In this example, the inventors cloned the ζ-chain sequence encoding human PD1 extracellular fragment sequence, CD28 transmembrane and intracellular fragment and T cell receptor into a lentiviral vector containing EF-1 promoter Above, during the cloning process, the selected restriction enzymes are XbaI and NotI double enzyme digestion, and NotI and XhoI double enzyme digestion, through enzyme digestion, ligation, screening and amplification of the target plasmid, a lentivirus expressing the recombinant receptor is generated Plasmid (LV-PD1-CD28-CD3ζ(LV-PD1-CD28z). Sequences containing the IRES and expressing the non-functional EGFR receptor were cloned into the LV-PD1-CD28-CD3ζ vector plasmid, constructed as LV-PD1-CD28-CD3ζ -tEGFR(M)(LV-PD1-CD28z / M). The sequence of shRNA containing U6 and silencing ...

Embodiment 2

[0280] Example 2 Anti-EGFR antibodies can effectively kill and clear T lymphocytes co-expressing non-functional EGFR receptors, recombinant receptors and shRNA (shPD1, iPD1) that silences PD1

[0281] In this example, peripheral blood lymphocytes were obtained from anonymous blood donors. Peripheral blood lymphocytes were separated by gradient centrifugation using Ficoll-Hypaque. T lymphocytes and T cell activator magnetic beads CD3 / CD28 (purchased from Invitrogen, Carlsbad, CA) in 5% CO 2 , Incubated at 37 degrees Celsius for 72 hours, the medium was added with 2mmol / L glutamine, 10% high temperature inactivated fetal calf serum (FCS) (purchased from Sigma-Aldrich Co.) and 100U / ml of penicillin / chain RPMI medium 1640 (purchased from Invitrogen Gibco Cat. no. 12633-012) with antimycin double antibody. After activating and culturing for 72 hours, the cells were rinsed with washing solution to wash away the magnetic beads. The T cells were planted on a cell culture dish lined...

Embodiment 3

[0282] Example 3 Cytolytic Ability of T Lymphocyte Tumor Cells Co-expressing Non-functional EGFR Receptor, shPD1 and PD1-CD28-CD3ζ Recombinant Receptor

[0283] In this example, peripheral blood lymphocytes were separated by gradient centrifugation, and the gradient centrifuge was Ficoll-Hypaque. T lymphocytes and T cell activator magnetic beads CD3 / CD28 (purchased from Invitrogen, Carlsbad, CA) were incubated at 5% CO2, 37 degrees Celsius for 72 hours, the medium was added with 2mmol / L glutamine, 10% high temperature Inactivated fetal calf serum (FCS) (purchased from Sigma-Aldrich Co.) and 100 U / ml penicillin / streptomycin double antibody RPMI medium 1640 (purchased from Invitrogen Gibco Cat. no. 12633-012). After activating and culturing for 72 hours, the cells were rinsed with washing solution to wash away the magnetic beads. The T cells were planted on a cell culture dish lined with recombinant fibronectin fragments (FN ch-296; Retronectin), and transduced with lentiviruse...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention puts forward a transgenic lymphocyte, a construct and a cancer treatment composition. A cell immune checkpoint of the transgenic lymphocyte is silenced and can be used for expression ofa recombinant receptor, and the recombinant receptor includes: a cell immune checkpoint molecule fragment; an immunostimulation molecule fragment; and a T cell receptor zeta chain. The transgenic lymphocyte has the characteristic of resistance to tumor cell mediated immunosuppression, and has significantly strengthened tumor cell killing ability.

Description

technical field [0001] The present invention relates to the field of biomedicine. Specifically, the present invention relates to the co-expression and application of recombinant immune checkpoint receptors and immune checkpoint inhibitory molecules. More specifically, the present invention relates to recombinant receptors, nucleic acids, lentiviruses, and transgenic lymphocytes. , a construct, a method for preparing transgenic lymphocytes, a therapeutic composition for treating cancer, and a method for improving immune killing ability of lymphocytes. Background technique [0002] Cancer is a disease in which cells proliferate uncontrollably due to genetic mutations in cells. It has become a major threat to human health and one of the main causes of human death. The World Health Organization (WHO) pointed out in the "Global Cancer Report 2014" that in 2012, the number of cancer patients and deaths worldwide increased rapidly, and nearly half of the new cancer cases occurred ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00C12N15/62C12N7/01C12N5/10A61K35/17A61P35/00
CPCC07K19/00C12N5/10C12N15/62A61P35/00A61K39/464429A61K39/4611
Inventor 陈思毅
Owner LIFESEQ LTDRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com